We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$43.5B
AUM Growth
+$8.16B
(+23%)
Cap. Flow
+$4.5B
Cap. Flow
% of AUM
10.34%
Top 10 Holdings %
Top 10 Hldgs %
11.55%
Holding
3,819
New
249
Increased
1,063
Reduced
1,013
Closed
119
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AT&T
T
|
+$424M |
| 2 |
Kenvue
KVUE
|
+$415M |
| 3 |
Cummins
CMI
|
+$374M |
| 4 |
Bunge Global
BG
|
+$310M |
| 5 |
Newell Brands
NWL
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$423M |
| 2 |
Qualcomm
QCOM
|
+$413M |
| 3 |
D.R. Horton
DHI
|
+$401M |
| 4 |
Booking.com
BKNG
|
+$397M |
| 5 |
Phillips 66
PSX
|
+$389M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.42% |
| 2 | Energy | 16.95% |
| 3 | Industrials | 12.39% |
| 4 | Healthcare | 10.91% |
| 5 | Technology | 10.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1251
Crinetics Pharmaceuticals
CRNX
$8.88B
| $47.3K | ﹤0.01% |
+1,011
| New | +$39.6K |
|
1252
Supernus Pharmaceuticals
SUPN
$2.71B
| $45.9K | ﹤0.01% |
1,346
+716
| +114% | +$21.3K |
|
1253
BridgeBio Pharma
BBIO
$16.7B
| $45.5K | ﹤0.01% |
+1,473
| New | +$50.1K |
|
1254
Dyne Therapeutics
DYN
$4.22B
| $45.4K | ﹤0.01% |
+1,600
| New | +$36.2K |
|
1255
Madrigal Pharmaceuticals
MDGL
$12.6B
| $45.4K | ﹤0.01% |
+170
| New | +$40.1K |
|
1256
Krystal Biotech
KRYS
$10.8B
| $44.8K | ﹤0.01% |
+252
| New | +$35K |
|
1257
Sarepta Therapeutics
SRPT
$1.66B
| $44.5K | ﹤0.01% |
+344
| New | +$42.1K |
|
1258
Badger Meter
BMI
$3.85B
| $44.5K | ﹤0.01% |
275
+58
| +27% | +$8.91K |
|
1259
Cars.com
CARS
$731M
| $44.2K | ﹤0.01% |
2,571
+919
| +56% | +$16.4K |
|
1260
Rhythm Pharmaceuticals
RYTM
$7.4B
| $44.1K | ﹤0.01% |
+1,018
| New | +$44.6K |
|
1261
BioMarin Pharmaceuticals
BMRN
$11.9B
| $43.9K | ﹤0.01% |
+503
| New | +$45K |
|
|
BPMC
1262
DELISTED
Blueprint Medicines
BPMC
| $43.9K | ﹤0.01% |
+463
| New | +$39.7K |
|
1263
Natera
NTRA
$36.6B
| $43.9K | ﹤0.01% |
+480
| New | +$36.1K |
|
|
CERE
1264
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $43.7K | ﹤0.01% |
+1,035
| New | +$43.5K |
|
1265
DoubleVerify
DV
$1.78B
| $43.7K | ﹤0.01% |
1,244
+560
| +82% | +$20.8K |
|
|
ALPN
1266
DELISTED
Alpine Immune Sciences Inc
ALPN
| $43.4K | ﹤0.01% |
+1,095
| New | +$32.3K |
|
1267
Immunovant
IMVT
$7.99B
| $43.4K | ﹤0.01% |
+1,343
| New | +$49K |
|
1268
Revolution Medicines
RVMD
$39B
| $42.7K | ﹤0.01% |
+1,326
| New | +$39.3K |
|
1269
Alnylam Pharmaceuticals
ALNY
$38.1B
| $42.6K | ﹤0.01% |
+285
| New | +$47.5K |
|
1270
Altimmune
ALT
$583M
| $42.3K | ﹤0.01% |
+4,159
| New | +$42.3K |
|
1271
Roivant Sciences
ROIV
$23.9B
| $42.1K | ﹤0.01% |
+3,999
| New | +$43.1K |
|
1272
Ionis Pharmaceuticals
IONS
$9.02B
| $42.1K | ﹤0.01% |
+971
| New | +$46.3K |
|
1273
Vericel Corp
VCEL
$2.38B
| $41.9K | ﹤0.01% |
+805
| New | +$35.3K |
|
1274
BlackLine
BL
$1.94B
| $41.7K | ﹤0.01% |
+646
| New | +$39.2K |
|
1275
Insmed
INSM
$22.6B
| $41.7K | ﹤0.01% |
+1,536
| New | +$43K |
|
Similar funds
SAM
Pacer Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, Pacer Advisors held 3,819 positions worth $43.5B, up 23% from $35.3B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Pacer Advisors deployed $4.5B of net new capital in Q1 2024, opening 249 new positions and adding to 1,063 existing holdings. Its largest new stake was Hanesbrands: 32,772,533 shares worth $190M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 19% a quarter earlier, followed by Energy and Industrials.
On the sell side, the largest reduction was AbbVie, an estimated $423M trimmed.
- Pacer Advisors's largest Q1 2024 buy was Hanesbrands: 32,772,533 shares worth $190M.
- Pacer Advisors added most to AT&T in Q1 2024, an estimated $424M increase.
- Pacer Advisors's biggest Q1 2024 reduction was AbbVie, cutting an estimated $423M.
- Pacer Advisors fully exited Tri Pointe Homes in Q1 2024, selling an estimated $139M.
- Pacer Advisors's ten largest holdings make up 12% of its $43.5B portfolio in Q1 2024.
- Pacer Advisors opened 249 new positions and closed 119 in Q1 2024.
- Pacer Advisors's portfolio value rose 23% quarter-over-quarter to $43.5B.
Based on Pacer Advisors's 13F filing for Q1 2024, filed 10 May 2024.